Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study

Combination therapy with lansoprazole and cholecalciferol is associated with a slower decline in residual beta-cell function and lower insulin requirements in children with recent onset type 1 diabetes: results of a pilot study

Abstract Objective To investigate the effects of combination therapy with cholecalciferol and lansoprazole on residual β-cell function and glycemic control in children with new-onset type 1 diabetes. Methods Children aged 6-12 years with type 1 diabetes were allocated to receive cholecalciferol an...

Full description

Bibliographic Details
Main Authors: Raghunatha Reddy, Devi Dayal, Naresh Sachdeva, Savita Verma Attri, Vinod Kumar Gupta
Format: Article
Language:English
Published: Instituto Israelita de Ensino e Pesquisa Albert Einstein 2022-11-01
Series:Einstein (São Paulo)
Subjects:
Diabetes mellitus
type 1
Blood glucose
Glycated hemoglobin A
Fasting
C-peptide
Drug tapering
Glycemic control
Cholecalciferol
Lansoprazole
Online Access:http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082022000100282&tlng=en

Internet

http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082022000100282&tlng=en

Similar Items